A Case of Chemotherapy-Refractory “THRLBCL like Transformation of NLPHL” Successfully Treated with Lenalidomide
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a subtype of nonclassical Hodgkin lymphoma (HL). It resembles non-Hodgkin lymphoma (NHL), by expressing classic B cell markers such as CD20 and CD79a however lacks definitive HL markers (such as CD15 and CD30). T cell histiocyte-rich large B...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2018/6137454 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551935964610560 |
|---|---|
| author | Mamatha Siricilla Lydia Irwin Andres Ferber |
| author_facet | Mamatha Siricilla Lydia Irwin Andres Ferber |
| author_sort | Mamatha Siricilla |
| collection | DOAJ |
| description | Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a subtype of nonclassical Hodgkin lymphoma (HL). It resembles non-Hodgkin lymphoma (NHL), by expressing classic B cell markers such as CD20 and CD79a however lacks definitive HL markers (such as CD15 and CD30). T cell histiocyte-rich large B cell lymphoma (THRLBCL), on the other hand, is a distinct entity classified under NHL and considered a variant of diffuse large B cell lymphoma (DLBCL). NLPHL can look morphologically and immunologically similar to THRLBCL and often poses a diagnostic challenge. Neoplastic cells in both NLPHL and THRLBCL express B cell markers and are typically scattered in a background of reactive cells. The two major differences are the background cell type and the morphologic pattern. Despite having a phenotypic resemblance, they have distinct biologic behavior and clinical course. NLPHL typically has an indolent course, and THRLBCL has an aggressive course. Hence, differentiating these two entities is critical not only for prognosis but for treatment purposes. Of note, NLPHL has a small risk of transformation to an aggressive lymphoma such as THRLBCL. |
| format | Article |
| id | doaj-art-2bdc5fc1d6cf494e9c6def1251f3067c |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-2bdc5fc1d6cf494e9c6def1251f3067c2025-02-03T06:00:05ZengWileyCase Reports in Oncological Medicine2090-67062090-67142018-01-01201810.1155/2018/61374546137454A Case of Chemotherapy-Refractory “THRLBCL like Transformation of NLPHL” Successfully Treated with LenalidomideMamatha Siricilla0Lydia Irwin1Andres Ferber2MD Anderson Cooper Cancer Center, Cooper University Hospital, Camden, NJ, USAMD Anderson Cooper Cancer Center, Cooper University Hospital, Camden, NJ, USAMD Anderson Cooper Cancer Center, Cooper University Hospital, Camden, NJ, USANodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a subtype of nonclassical Hodgkin lymphoma (HL). It resembles non-Hodgkin lymphoma (NHL), by expressing classic B cell markers such as CD20 and CD79a however lacks definitive HL markers (such as CD15 and CD30). T cell histiocyte-rich large B cell lymphoma (THRLBCL), on the other hand, is a distinct entity classified under NHL and considered a variant of diffuse large B cell lymphoma (DLBCL). NLPHL can look morphologically and immunologically similar to THRLBCL and often poses a diagnostic challenge. Neoplastic cells in both NLPHL and THRLBCL express B cell markers and are typically scattered in a background of reactive cells. The two major differences are the background cell type and the morphologic pattern. Despite having a phenotypic resemblance, they have distinct biologic behavior and clinical course. NLPHL typically has an indolent course, and THRLBCL has an aggressive course. Hence, differentiating these two entities is critical not only for prognosis but for treatment purposes. Of note, NLPHL has a small risk of transformation to an aggressive lymphoma such as THRLBCL.http://dx.doi.org/10.1155/2018/6137454 |
| spellingShingle | Mamatha Siricilla Lydia Irwin Andres Ferber A Case of Chemotherapy-Refractory “THRLBCL like Transformation of NLPHL” Successfully Treated with Lenalidomide Case Reports in Oncological Medicine |
| title | A Case of Chemotherapy-Refractory “THRLBCL like Transformation of NLPHL” Successfully Treated with Lenalidomide |
| title_full | A Case of Chemotherapy-Refractory “THRLBCL like Transformation of NLPHL” Successfully Treated with Lenalidomide |
| title_fullStr | A Case of Chemotherapy-Refractory “THRLBCL like Transformation of NLPHL” Successfully Treated with Lenalidomide |
| title_full_unstemmed | A Case of Chemotherapy-Refractory “THRLBCL like Transformation of NLPHL” Successfully Treated with Lenalidomide |
| title_short | A Case of Chemotherapy-Refractory “THRLBCL like Transformation of NLPHL” Successfully Treated with Lenalidomide |
| title_sort | case of chemotherapy refractory thrlbcl like transformation of nlphl successfully treated with lenalidomide |
| url | http://dx.doi.org/10.1155/2018/6137454 |
| work_keys_str_mv | AT mamathasiricilla acaseofchemotherapyrefractorythrlbclliketransformationofnlphlsuccessfullytreatedwithlenalidomide AT lydiairwin acaseofchemotherapyrefractorythrlbclliketransformationofnlphlsuccessfullytreatedwithlenalidomide AT andresferber acaseofchemotherapyrefractorythrlbclliketransformationofnlphlsuccessfullytreatedwithlenalidomide AT mamathasiricilla caseofchemotherapyrefractorythrlbclliketransformationofnlphlsuccessfullytreatedwithlenalidomide AT lydiairwin caseofchemotherapyrefractorythrlbclliketransformationofnlphlsuccessfullytreatedwithlenalidomide AT andresferber caseofchemotherapyrefractorythrlbclliketransformationofnlphlsuccessfullytreatedwithlenalidomide |